Sinovac Biotech Ltd. Achievements in 2004 and Anticipated Goals for 2005

Strategic Insights -

Sinovac Biotech Ltd., a leading biotechnology company in China, has made significant strides in research and development, commercialization, and sales of human vaccines in 2004. The company gained approval for SARS vaccine clinical trials on humans in January 2004 and completed its split flu influenza vaccine clinical trials in April, filing for a drug application with the Chinese State Food and Drug Administration. Sinovac received research funding support from the US National Institute of Health and more than $1 million in research funding from the Chinese state government for its SARS vaccine development program. The company also received an additional $1.2 million in research funding from the Chinese government and submitted vaccine registration applications for its hepatitis A vaccine in nine countries.

Key Takeaways:

  • Sinovac gained approval to conduct SARS vaccine clinical trials on humans on January 19, 2004.
  • The company completed its split flu influenza vaccine clinical trials in April 2004 and filed for a drug application with the Chinese State Food and Drug Administration.
  • Sinovac received $1 million in research funding from the Chinese state government for its SARS vaccine development program on June 1, 2004.
  • The company received an additional $1.2 million in research funding from the Chinese government for its SARS vaccine development program on July 20, 2004.
  • Sinovac submitted vaccine registration applications for its hepatitis A vaccine in nine countries, including Brazil, Indonesia, and Vietnam.
  • Healive revenue grew more than 230% over 2003, with sales of approximately $6.5 million.
  • Sinovac announced preliminary success of its inactivated SARS vaccine phase 1 trial, which effectively induced SARS-neutralizing antibodies and showed no significant side-effects on December 5, 2004.

Statistics:

  • Sinovac sold over 1 million doses of Healive in 2004, generating sales of approximately $6.5 million.
  • Healive revenue grew more than 230% over 2003.
  • The company received $2.2 million in research funding from the Chinese government and the US National Institute of Health for its SARS vaccine development program.
  • Sinovac submitted vaccine registration applications for its hepatitis A vaccine in nine countries.

Sources:

  • Sinovac Biotech Ltd. press releases and official communications.
  • Health & Medicine Week, Vol. 2005, via NewsRx.com & NewsRx.net.